All recently introduced new myeloma drugs have mechanisms of activity not targeting eEF1A2; this fact, together with the favorable safety profile and the lack of overlapping toxicities with commonly used agents, places plitidepsin as an alternative option for designing combinations or even for its administration after relapse in patients treated with immunotherapy. The gene discussed is EEF1A2; the disease is plasma cell myeloma.